GlassScriptPhysician profile
Leigh A Gressley
NPI 1063665875
$8,583.32
in general payments reported to CMS, 2019-2025
53 companies · $1,929 in 2025
The $1,929 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,984 · 2022: $1,592 · 2023: $1,850 · 2024: $1,229 · 2025: $1,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,007.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,942.89 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $692.12 | 2021-2025 | |
| Amgen INC. | $540.09 | 2021-2024 | Aimovig, Uplizna |
| Biogen, INC. | $389.06 | 2021-2025 | Vumerity, Tysabri |
| Allergan, INC. | $376.55 | 2021-2022 | |
| Eisai INC. | $373.94 | 2023-2025 | |
| Ucb, INC. | $332.57 | 2021-2025 | Briviact, Rystiggo |
| Genentech USA, INC. | $329.45 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Lilly USA, LLC | $323.72 | 2021-2025 | Emgality, Reyvow, Amyvid |
| Alexion Pharmaceuticals, INC. | $283.96 | 2022-2025 | Ultomiris |
| Argenx US, INC. | $266.02 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $259.56 | 2021-2023 | Privigen, Hizentra |
| Impel Pharmaceuticals INC. | $250.91 | 2022-2023 | Trudhesa |
| Neurocrine Biosciences, INC. | $171.55 | 2022-2025 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $159.28 | 2021-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Gressley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.